LGALS9 and neoplasm: Combined anti-Gal-9 (OTI1G3) and doxorubicin chemotherapeutic treatment enhanced T cell cytotoxicity and reduced tumor growth more efficiently than respective monotherapies in mice bearing EMT6 tumors [157].